First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease

David G Rizik; Maulik G Shah; Robert F Burke

doi:10.1002/ccd.26708

First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease

Catheter Cardiovasc Interv. 2016 Nov 15;88(6):899-901. doi: 10.1002/ccd.26708. Epub 2016 Aug 22.

Authors

David G Rizik¹, Maulik G Shah², Robert F Burke²

Affiliations

¹ HonorHealth and the Scottsdale-Lincoln Health Network, Scottsdale, Arizona.
² HonorHealth, Scottsdale, Arizona.

PMID: 27545489
DOI: 10.1002/ccd.26708

Abstract

Drug eluting stents are considered the "gold standard" for the percutaneous treatment of coronary artery disease. Recent publications have suggested that a reasonable alternative, in well selected cases, may be the ABSORBTM bioresorbable vascular scaffold (BVS) stent. © 2016 Wiley Periodicals, Inc.

Keywords: bioabsorbable devices/polymers; coronary artery disease; stent restenosis.

Publication types

Case Reports

MeSH terms

Absorbable Implants*
Aged
Aged, 80 and over
Coronary Angiography
Coronary Artery Disease / diagnosis
Coronary Artery Disease / surgery*
Coronary Vessels / diagnostic imaging
Coronary Vessels / surgery*
Drug Approval*
Drug-Eluting Stents*
Humans
Male
Middle Aged
Prosthesis Design
Tissue Scaffolds*
United States
United States Food and Drug Administration